<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Effects of free fatty acids (FFAs) on endogenous <z:chebi fb="105" ids="17234">glucose</z:chebi> production (EGP) and gluconeogenesis (GNG) were examined in healthy subjects (n = 6) during stepwise increased Intralipid/<z:chebi fb="5" ids="28304">heparin</z:chebi> infusion (plasma FFAs 0.8+/-0.1, 1.8+/-0.2, and 2.8+/-0.3 mmol/l) and during <z:chebi fb="3" ids="17754">glycerol</z:chebi> infusion (plasma FFAs approximately 0.5 mmol/l) </plain></SENT>
<SENT sid="1" pm="."><plain>Rates of EGP were determined with D-[6,6-2H2]<z:chebi fb="105" ids="17234">glucose</z:chebi> and contributions of GNG from 2H enrichments in carbons 2 and 5 of blood <z:chebi fb="105" ids="17234">glucose</z:chebi> after 2H2O ingestion </plain></SENT>
<SENT sid="2" pm="."><plain>Plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> concentrations decreased by approximately 10% (P &lt; 0.01), whereas plasma <z:e sem="disease" ids="C0020459" disease_type="Disease or Syndrome" abbrv="">insulin increased</z:e> by approximately 47% (P = 0.02) after 9 h of <z:chebi fb="23" ids="18059">lipid</z:chebi> infusion </plain></SENT>
<SENT sid="3" pm="."><plain>EGP declined from 9.3+/-0.5 (<z:chebi fb="23" ids="18059">lipid</z:chebi>) and 9.0+/-0.8 pmol x kg(-1) x min(-1) (<z:chebi fb="3" ids="17754">glycerol</z:chebi>) to 8.4+/-0.5 and 8.2+/-0.7 micromol x kg(-1) x min(-1), respectively (P &lt; 0.01) </plain></SENT>
<SENT sid="4" pm="."><plain>Contribution of GNG similarly rose (P &lt; 0.01) from 46+/-4 and 52+/-3% to 65+/-8 and 78+/-7% </plain></SENT>
<SENT sid="5" pm="."><plain>To exclude interaction of FFAs with insulin secretion, the study was repeated at fasting plasma insulin (approximately 35 pmol/l) and glucagon (approximately 90 ng/ml) concentrations using somatostatin-insulin-glucagon clamps </plain></SENT>
<SENT sid="6" pm="."><plain>Plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> increased by approximately 50% (P &lt; 0.005) during <z:chebi fb="23" ids="18059">lipid</z:chebi> but decreased by approximately 12% during <z:chebi fb="3" ids="17754">glycerol</z:chebi> infusion (P &lt; 0.005) </plain></SENT>
<SENT sid="7" pm="."><plain>EGP remained unchanged over the 9-h period (9.9+/-1.2 vs. 9.0+/-1.1 micromol x kg(-1) x min(-1)) </plain></SENT>
<SENT sid="8" pm="."><plain>GNG accounted for 62+/-5 (<z:chebi fb="23" ids="18059">lipid</z:chebi>) and 60+/-6% (<z:chebi fb="3" ids="17754">glycerol</z:chebi>) of EGP at time 0 and rose to 74+/-3% during <z:chebi fb="23" ids="18059">lipid</z:chebi> infusion only (P &lt; 0.05 vs. <z:chebi fb="3" ids="17754">glycerol</z:chebi>: 64+/-4%) </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, high plasma FFA concentrations increase the percent contribution of GNG to EGP and may contribute to increased rates of GNG in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>